Eye injury, inflammatorydiseases, and exposure to toxic chemicals such as pesticides and acids used inmanufacturing processes are some of the major causes of uveitis. Anterioruveitis is an inflammation of the middle part of the eye, which furtherincludes the other vital part responsible for the vision such as iris, ciliarybody, and other adjacent tissues.
The global UveitisTreatment Market is estimated to account for US$ 648.4 Mn in terms of valuein 2020 and is expected to reach US$ 1,036.0 Mn by the end of 2027.
Global Uveitis Treatment Market:Drivers
Positive outcomes in clinicaltrials are expected to propel growth of the global uveitis treatment over theforecast period. For instance, in June 2019, Alimera Sciences, Inc. announcedthree-year follow-up data from the Phase 3 clinical trial for ILUVIEN 190micrograms intravitreal implant in applicator, for the prevention of relapse inrecurrent non-infectious uveitis affecting the posterior segment of the eye.
Global Uveitis Treatment Market:Opportunities
R&D in uveitis is expected tooffer lucrative growth opportunities for players in the global uveitistreatment over the forecast period. For instance, in May 2020, researchers fromNational Cheng Kung University, Taiwan, identified a novel role of reactiveoxygen species in the pathogenesis of experimental autoimmune uveitis andsuggested a potential antioxidant role for the treatment of autoimmune uveitisin the future.
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/1094
Global Uveitis Treatment Market:Restraints
Insufficient funding for R&Din eye health is expected to hinder growth of the market. For instance,according to Peter McCluskey, Professor of Clinical Ophthalmology and EyeHealth, and Director of Save Sight Institute at the Faculty of Medicine andHealth at the University of Sydney, (as reported to MI Vision, an ophthalmicjournal, in July 2019), research grants from the National Health and MedicalResearch Council (Australia) are down from 30% to around 7%.
Key Takeaways:
The global uveitis treatmentmarket was valued at US$ 605.7 Mn in 2019 and is forecast to reach a value ofUS$ 1,036.0 Mn by 2027 at a CAGR of 6.9% between 2020 and 2027. Major factordriving the growth of global uveitis treatment market during the forecastperiod include high prevalence of uveitis, and number of treatment options.
Corticosteroids held dominantposition in the global uveitis treatment market in 2019, accounting for 21.1%share in terms of value, followed by Monoclonal Antibodies and Antibiotics,respectively. Corticosteroids are a primary treatment options for treatinguveitis, and can be administered via multiple routes such as topical, and oral.
Market Trends
The market is witnessing virtualconferences due to Covid-19. For instance, in June 2020, EyePointPharmaceuticals, Inc. presented at the Jefferies Virtual Healthcare Conference.
Major players in the market arefocused on adopting partnership strategies to enhance their market share. Forinstance, in March 2020, Clearside Biomedical, Inc. partnered with ArcticVision, a company focused on developing and commercializing innovativeophthalmology therapies in China and Asia, under which Arctic Vision will getan exclusive license for the commercialization and development of XIPERE(triamcinolone acetonide suprachoroidal injectable suspension for the treatmentof macular edema associated with uveitis) in Greater China (mainland China,Hong Kong, Macau and Taiwan) and South Korea.
Browse ResearchReport: https://www.coherentmarketinsights.com/market-insight/uveitis-treatment-market-1094
Global Uveitis Treatment Market:Competitive Landscape
Major players operating in theglobal uveitis treatment market include, Allergan, Inc., Novartis AG, ValeantPharmaceuticals International, Inc., Galapagos, EyePoint Pharmaceuticals, Inc.,Clearside Biomedical, Inc., AbbVie Inc., Tarsius Pharma, Eyegate Pharmaceuticals, Inc., Alimera SciencesInc., and pSivida Corp.
Global Uveitis Treatment Market:Key Developments
April 2020: Alimera Sciences,Inc. reported that international net revenue increased 23% to approximately US$7.5 million in Q1 2020, compared to approximately US$ 6.1 million for the sameperiod during 2019, owing to growth in the company’s DME business in directmarkets and the launches of ILUVIEN’s uveitis indication in Germany and the U.K.in the second half of 2019.
April 2020: Clearside Biomedical,Inc. and Bausch Health amended and revised their partnership for XIPERE(triamcinolone acetonide suprachoroidal injectable suspension for the treatmentof macular edema associated with uveitis), under which Bausch + Lomb has beengranted exclusive options for the right to commercialize and develop XIPERE inEurope and the U.K., Australia and New Zealand, and South America and Mexico.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/1094
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN: +050-5539-1737
